Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

122.81 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
66 67 Next >
Gilead Sciences Announces Second Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Wall Street Rallies As Economic Concerns Recede, Tech Flexes Its Muscles, Semiconductors Soar: What's Driving Markets Thursday?
Investor risk sentiment is showing greater conviction on Thursday, with all indices and major stock sectors in the green, after Wall Street failed to hold onto opening gains and closed in the red the... 
Via Benzinga
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Gilead Sciences's Options Frenzy: What You Need to Know
 
Via Benzinga
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Wall Street Set For Uneventful Start Ahead Of Jobless Claim Data, VIX Rises: Strategist Says Market May Remain Vulnerable Until...
U.S. stocks are set for a mixed start on Thursday as concerns regarding the economy and incremental yen carry trade unwinding remain an undercurrent. Traders may be keen to receive the jobless claims... 
Via Benzinga
Topics Economy Stocks
Four Stocks To Watch This Week - Monday, August 5
The unease we've been mentioning over the past several weeks has borne bearish fruit in the last two weeks. The good news is that stocks are correcting across the board, which means they will... 
Via Talk Markets
2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off
Dividend stocks are great; cheap dividend stocks are better. 
Via The Motley Fool
This Is What Whales Are Betting On Gilead Sciences
 
Via Benzinga
Breaking Down Gilead Sciences: 10 Analysts Share Their Views
 
Via Benzinga
Check Out What Whales Are Doing With GILD
 
Via Benzinga
Q3’s Rising Stars: 3 Nasdaq Stocks for Your Must-Watch List
Traders are rushing out of overvalued and overhyped Nasdaq stocks, making it a great time to rotate into these Nasdaq stocks to watch. 
Via InvestorPlace
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The Stock Whisper Index provides a weekly list of five stocks that are seeing above-average interest from readers. 
Via Benzinga
The Top 3 Biotech Stocks to Buy Now Summer 2024
These biotech stocks are well-positioned to generate high returns for investors due to their significant growth prospects. 
Via InvestorPlace
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates. 
Via InvestorPlace
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Nasdaq 100 Falls To 7-Week Lows, Marks Worst 2-Day Drop In Nearly 2 Years As Tech Rout Rages On
Nasdaq 100 index falls to its lowest level since June amid volatility. Despite a brief boost from Q2 GDP growth and decreasing prices, it dropped 4.7% in 2 sessions. 
Via Benzinga
Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Gilead Sciences, Inc.
Via Business Wire
Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
From Gilead Sciences, Inc.
Via Business Wire
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
Good bargains still abound in the market, and two of the stocks below offer fat dividends as well. 
Via The Motley Fool
Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price
Gilead Sciences' lenacapavir, marketed as Sunlenca, is under scrutiny for its $42,250 annual price despite research suggesting it could be produced for $40. Campaigners are urging for global price... 
Via Benzinga
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
From Gilead Sciences, Inc.
Via Business Wire
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient... 
Via Benzinga
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
HC Wainwright initiated coverage on AnaptysBio with a Buy rating and a $55 price target. AnaptysBio focuses on immunology therapeutics with a promising pipeline. 
Via Benzinga
Biotech Bull Market Is Intact But SMIDs Are Too Volatile
It was another wild week for the market as it had to contend with a lot of news. 
Via Talk Markets
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
From Gilead Sciences, Inc.
Via Business Wire
This Hidden Gem Vanguard ETF Is Chock-Full of Magnificent Stocks. Here's Why It's a Buy Now.
This fund has a basket of growth, income, and value stocks. 
Via The Motley Fool
Topics ETFs
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
Evaluating and making money from biotech stocks is incredibly difficult. These three ideas should help your quest if buying in July. 
Via InvestorPlace
Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.